MacroGenics, Inc. (MGNX)
4.14
+0.01
(+0.24%)
USD |
NASDAQ |
Sep 18, 16:00
4.14
0.00 (0.00%)
After-Hours: 20:00
MacroGenics Free Cash Flow : -65.54M for June 30, 2026
Free Cash Flow Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| June 30, 2026 | -65.54M |
| March 31, 2026 | -71.69M |
| December 31, 2025 | -82.95M |
| September 30, 2025 | -164.76M |
| June 30, 2025 | -74.58M |
| March 31, 2025 | -72.40M |
| December 31, 2024 | -72.08M |
| September 30, 2024 | -61.71M |
| June 30, 2024 | -157.02M |
| March 31, 2024 | -113.88M |
| December 31, 2023 | -79.97M |
| September 30, 2023 | -22.38M |
| June 30, 2023 | 3.134M |
| March 31, 2023 | -44.66M |
| December 31, 2022 | -90.58M |
| September 30, 2022 | -175.19M |
| June 30, 2022 | -181.90M |
| March 31, 2022 | -179.48M |
| December 31, 2021 | -150.03M |
| September 30, 2021 | -103.44M |
| June 30, 2021 | -112.69M |
| March 31, 2021 | -102.07M |
| December 31, 2020 | -117.80M |
| September 30, 2020 | -148.00M |
| June 30, 2020 | -139.99M |
| Date | Value |
|---|---|
| March 31, 2020 | -152.28M |
| December 31, 2019 | -138.56M |
| September 30, 2019 | -127.21M |
| June 30, 2019 | -150.24M |
| March 31, 2019 | -164.05M |
| December 31, 2018 | -178.19M |
| September 30, 2018 | -49.16M |
| June 30, 2018 | -49.17M |
| March 31, 2018 | -23.99M |
| December 31, 2017 | -15.00M |
| September 30, 2017 | -145.48M |
| June 30, 2017 | -56.47M |
| March 31, 2017 | -57.14M |
| December 31, 2016 | -55.06M |
| September 30, 2016 | -52.30M |
| June 30, 2016 | -110.65M |
| March 31, 2016 | -100.20M |
| December 31, 2015 | -22.86M |
| September 30, 2015 | -18.04M |
| June 30, 2015 | -22.61M |
| March 31, 2015 | 0.7211M |
| December 31, 2014 | -36.44M |
| September 30, 2014 | -16.72M |
| June 30, 2014 | -1.968M |
| March 31, 2014 | -7.420M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Gilead Sciences, Inc. | 12.94B |
| Xencor, Inc. | -208.28M |
| ACADIA Pharmaceuticals, Inc. | 145.62M |
| Alnylam Pharmaceuticals, Inc. | 793.94M |
| Anika Therapeutics, Inc. | 0.562M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -40.75M |
| Cash from Investing (Quarterly) | 27.96M |
| Cash from Financing (Quarterly) | 60.17M |
| Free Cash Flow Per Share (Quarterly) | -0.6534 |
| Free Cash Flow to Equity (Quarterly) | -134.58M |
| Free Cash Flow to Firm (Quarterly) | -37.16M |
| Free Cash Flow Yield | -24.97% |